Patent: 7,132,554
✉ Email this page to a colleague
Summary for Patent: 7,132,554
Title: | Therapeutic synergy of anti-cancer compounds |
Abstract: | This invention relates to a synergistic therapeutic combination of anti-cancer compounds which comprises a) a taxane, and b) a substance that binds to the epidermal growth factor receptor (EGFR) and blocks the ability of epidermal growth factor (EGF) to intitiate receptor activities which results in tumor growth inhibition, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use. |
Inventor(s): | Rose; William C. (Pipersville, PA) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 11/079,064 |
Patent Claims: | see list of patent claims |
Details for Patent 7,132,554
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2024-03-16 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2024-03-16 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |